ArticleEuropean journal of heart failure2020

Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.

Phil McEwan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.